Interview: Veterinary Stem Cells – Gallant’s Quest for the First FDA-Approved MSC Therapy
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell therapies. By sourcing mesenchymal stem cells from uterine tissue collected during routine spays, it has built an off-the-shelf platform with consistent, high-yield cells and FDA-aligned manufacturing, with a potential first FDA…
